- Home
- CLPR vs COEP Comparison
CLPR vs COEP Comparison
Compare CLPR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | COEP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 161 | 7 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 72.7M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLPR | COEP |
|---|---|---|
| Price | $3.20 | $12.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 57.4K | 30.4K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 11.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $3.04 | $6.32 |
| 52 Week High | $4.68 | $21.41 |
Technical Indicators
Market Signals| Indicator | CLPR | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 48.81 |
| Support Level | $3.04 | $10.83 |
| Resistance Level | $3.96 | $13.12 |
| Average True Range (ATR) | 0.12 | 0.83 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 38.60 | 52.61 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.